• Login
    View Item 
    •   ORKA Home
    • Conditions, Lifestyle Factors & Interventions
    • Conditions
    • Cardiovascular Diseases
    • View Item
    •   ORKA Home
    • Conditions, Lifestyle Factors & Interventions
    • Conditions
    • Cardiovascular Diseases
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Cerebral venous thrombosis: a retrospective cohort study of 513,284 confirmed COVID-19 cases and a comparison with 489,871 people receiving a COVID-19 mRNA vaccine

    Thumbnail
    Date
    2021-04
    Author
    Taquet, Maxime
    Geddes, John R
    Harrison, Paul J
    Metadata
    Show full item record
    Citation
    Maxime Taquet, Masud Husain, John R Geddes, Sierra Luciano,Paul J Harrison. Cerebral venous thrombosis: a retrospective cohort study of 513,284 confirmed COVID-19 cases and a comparison with 489,871 people receiving a COVID-19 mRNA vaccine. medRxiv 2021.04.27.21256153
    Abstract
    Objectives To estimate the absolute risk of cerebral venous thrombosis (CVT) and portal vein thrombosis (PVT) in the two weeks following a diagnosis of COVID-19, and to assess the relative risks (RR) compared to influenza or the administration of an mRNA vaccine against COVID-19. Design Retrospective cohort study based on an electronic health records network Setting Linked records between primary and secondary care centres within 59 healthcare organisations, primarily in the USA Participants All patients with a confirmed diagnosis of COVID-19 between January 20, 2020 and March 25, 2021 were included (N=537,913, mean [SD] age: 46.2 [21.4] years; 54.9% females). Cohorts (matched for age, sex, and race) of participants diagnosed with influenza (N=392,424) or receiving the BNT162b2 or mRNA-1273 vaccine (N=366,869) were used for comparison. Main outcome measures Diagnosis of CVT (ICD-10 code I67.6) or PVT (ICD-10 code I81) within 2 weeks after a diagnosis of COVID-19. Results The incidence of CVT after COVID-19 diagnosis was 42.8 per million people (95% CI 28.5–64.2) including 35.3 per million (95% CI 22.6–55.2) first diagnoses. This was significantly higher than the CVT incidence in a matched cohort of patients with influenza (RR=3.83, 95% CI 1.56–9.41, P<0.001) and people who received an mRNA vaccine (RR=6.67, 95% CI 1.98–22.43, P<0.001). The incidence of PVT after COVID-19 diagnosis was 392.3 per million people (95% CI 342.8–448.9) including 175.0 per million (95% CI 143.0–214.1) first diagnoses. This was significantly higher than the PVT incidence in a matched cohort of patients with influenza (RR=1.39, 95% CI 1.06–1.83, P=0.02) and people who received an mRNA vaccine (RR=7.40, 95% CI 4.87–11.24, P<0.001). Mortality after CVT and PVT was 17.4% and 19.9% respectively. Conclusions The incidence of CVT and PVT is significantly increased after COVID-19. The data highlight the risk of serious thrombotic events in COVID-19 and can help contextualize the risks and benefits of vaccination in this regard.
    URI
    https://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/849
    Published online at:
    https://doi.org/10.1101/2021.04.27.21256153
    Collections
    • Cardiovascular Diseases [19]
    • Other Medical Trainee's publications [12]

    Oxford Health copyright © 2019
    Contact Us | Send Feedback | JSPUI
    Powered by KnowledgeArc
     

     

    Browse

    All of ORKACommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsContributor DisciplineThis CollectionBy Issue DateAuthorsTitlesSubjectsContributor Discipline

    My Account

    Login

    Researcher Profiles

    Researchers

    Oxford Health copyright © 2019
    Contact Us | Send Feedback | JSPUI
    Powered by KnowledgeArc